文献速递肺结节与肺癌

阿瑞匹坦治疗肺癌咳嗽:随机安慰剂对照试验及机制研究

Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights.
PubMed 文献 · Am J Respir Crit Care Med · 2021-01-01

阿瑞匹坦使清醒时咳嗽频率降低22.2%(95%CI 2.8-37.7%,P=0.03),24小时降低30.3%(95%CI 12.7-44.3,P=0.002),患者报告结局均显著改善。体外实验显示阿瑞匹坦显著抑制P物质诱导的迷走神经去极化。

要点

  • 阿瑞匹坦可降低肺癌患者清醒及24小时咳嗽频率。
  • 患者报告结局均显著改善。
  • P物质激活NK-1受体可能是肺癌咳嗽重要机制。

核心结论

  • P物质激活NK-1受体似乎是驱动肺癌咳嗽的重要机制,NK-1拮抗剂有望成为镇咳疗法。

研究设计与样本

  • 体外采用 grease-gap 记录 chamber 测定离体豚鼠和人迷走神经节段的去极化以评估机制。

主要发现

  • 阿瑞匹坦使清醒时咳嗽频率较安慰剂降低22.2%(95%CI 2.8-37.7%,P=0.03)。
  • 24小时咳嗽频率降低30.3%(95%CI 12.7-44.3,P=0.002)。
  • 睡眠期间咳嗽频率降低59.8%(95%CI 15.1-86.0,P=0.081)。
  • 患者报告结局均显著改善。
  • P物质可使豚鼠和人迷走神经去极化,阿瑞匹坦显著抑制P物质诱导的去极化,豚鼠抑制78%(P=0.0145),人迷走神经抑制94%(P=0.0145)。

临床怎么用

  • 对于肺癌伴烦人咳嗽患者,阿瑞匹坦可能作为镇咳治疗选择,但需结合个体情况评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Effective cough treatments are a significant unmet need in patients with lung cancer. Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors, a mechanism also implicated in cough.Objectives: To assess aprepitant in patients with lung cancer with cough and evaluate mechanisms in vagal nerve tissue.Methods: Randomized double-blind crossover trial of patients with lung cancer and bothersome cough. They received 3 days of aprepitant or matched placebo; after a 3-day washout, patients crossed to the alternative treatment. The primary endpoint was awake cough frequency measured at screening and Day 3 of each treatment; secondary endpoints included patient-reported outcomes. In vitro, the depolarization of isolated guinea pig and human vagus nerve sections in grease-gap recording chambers, indicative of sensory nerve activation, was measured to evaluate the mechanism.Measurements and Main Results: Twenty patients with lung cancer enrolled, with a mean age 66 years (±7.7); 60% were female and 80% had non-small cell cancer, 50% had advanced stage, and 55% had World Health Organization performance status 1. Cough frequency improved with aprepitant, reducing by 22.2% (95% confidence interval [CI], 2.8-37.7%) over placebo while awake (P = 0.03), 30.3% (95% CI, 12.7-44.3) over 24 hours (P = 0.002), and 59.8% (95% CI, 15.1-86.0) during sleep (P = 0.081). Patient-reported outcomes all significantly improved. Substance P depolarized both guinea pig and human vagus nerve. Aprepitant significantly inhibited substance P-induced depolarization by 78% in guinea pig (P = 0.0145) and 94% in human vagus (P = 0.0145).Conclusions: Substance P activation of NK-1 receptors appears to be an important mechanism driving cough in lung cancer, and NK-1 antagonists show promise as antitussive therapies.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Smith JA, Harle A, Dockry R, et al. Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights. Am J Respir Crit Care Med. 2021. PMID: 32966755. doi:10.1164/rccm.202006-2359OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。